Status:
UNKNOWN
Investigation on Risk Factors of Rheumatoid Arthritis Related Interstitial Lung Disease
Lead Sponsor:
First Affiliated Hospital of Chongqing Medical University
Conditions:
Rheumatoid Arthritis Associated Interstitial Lung Disease
Eligibility:
All Genders
18+ years
Brief Summary
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, characterized by chronic inflammatory bone and cartilage destruction. Although treatment including anti-tumor necrosis factor (...
Eligibility Criteria
Inclusion
- 1\. Diagnosis of rheumatoid arthritis patients based on the 2010 ACR/EULAR RA classification criteria; 2. age ≥18 years; 3. Interstitial lung disease was diagnosed by lung high resolution computed tomography (HRCT)
Exclusion
- 1\. age \<years; 2. Being treated with urate-lowering medications; 3. Other systemic/organ specific autoimmune diseases other than rheumatoid arthritis (such as SLE, ANCA associated vasculitis, pSS, SSc, myositis, etc.); 4.Tumor, pulmonary tuberculosis, glomerular filtration rate less than 30ml/min/1.73m2
Key Trial Info
Start Date :
June 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06036537
Start Date
June 1 2023
End Date
June 1 2025
Last Update
September 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chongqing General Hospital
Chongqing, Chongqing Municipality, China, 401147